Tabimorelin

CAS: 193079-69-5

Ref. TR-T003500

Informação sobre produto

• Nome: Tabimorelin
• Sinónimos: (R)-alpha-((E)-5-Amino-N,5-dimethyl-2-hexenamido)-N-methyl-N-((R)-alpha-(methylcarbamoyl)phenethyl)-2-naphthalenepropionamide, <span class="text-smallcaps">D</smallcap>-Phenylalaninamide, N-[(2E)-5-amino-5-methyl-1-oxo-2-hexen-1-yl]-N-methyl-3-(2-naphthalenyl)-<smallcap>D</span>-alanyl-N,N^α-dimethyl-, <span class="text-smallcaps">D</smallcap>-Phenylalaninamide, N-[(2E)-5-amino-5-methyl-1-oxo-2-hexenyl]-N-methyl-3-(2-naphthalenyl)-<smallcap>D</span>-alanyl-N,N^α-dimethyl-, N-[(2E)-5-Amino-5-methyl-1-oxo-2-hexen-1-yl]-N-methyl-3-(2-naphthalenyl)-<span class="text-smallcaps">D</smallcap>-alanyl-N,N^α-dimethyl-<smallcap>D</span>-phenylalaninamide, N-[(2E)-5-amino-5-methylhex-2-enoyl]-N-methyl-3-(naphthalen-2-yl)-D-alanyl-N,Nα-dimethyl-D-phenylalaninamide, Nn 703, Nnc 26-0703, Tabimorelin [INN], Unii-L51Cbe03Kf
• CAS: 193079-69-5

Descrição

Applications NN703 (Tabimorelin) is an orally active growth hormone (GH) secretagogue intended for use as an alternative to daily injections of GH. In vitro studies in human liver microsomes have indicated that NN703 is a mechanism-based inhibitor of CYP3A4.
References Fabre, G., et al.: Biochem. Pharmacol., 37, 4389 (1988), Thummel, K., et al.: Clin. Pharmacol. Ther., 59, 491 (1996), Yu, D., et al.: J. Clin. Pharmacol., 39, 1203 (1999),

• Marca: TRC

Propriedades químicas

• Peso molecular: 528.68
• Fórmula: C₃₂H₄₀N₄O₃
• Cor/forma: White to Off-White Solid
• InChI: InChI=1S/C32H40N4O3/c1-32(2,33)19-11-16-29(37)35(4)28(22-24-17-18-25-14-9-10-15-26(25)20-24)31(39)36(5)27(30(38)34-3)21-23-12-7-6-8-13-23/h6-18,20,27-28H,19,21-22,33H2,1-5H3,(H,34,38)/b16-11+/t27-,28-/m1/s1
• Chave InChI: InChIKey=WURGZWOTGMLDJP-GBDBBNHTSA-N
• SMILES: CNC(=O)[C@@H](Cc1ccccc1)N(C)C(=O)C(Cc1ccc2ccccc2c1)N(C)C(=O)/C=C/CC(C)(C)N